GLP-1 agonists are on a tear lately, with Eli Lilly’s Q3 revenue up 54% YoY thanks to volume growth from Mounjaro and Zepbound. Meanwhile, the Trump administration has recently struck a deal with Lilly and Novo Nordisk to bring the cost of such drugs down by 65-75% through a new D2C marketplace called TrumpRx that will launch in early ‘26. Over the past few years, HNGRY has been closely monitoring the slow rise of prebiotic fiber and resistant starch found in supplements like Supergut, Bio.me, and ZOE’s Daily30+ as well as better-for-you foods like 3 Farm Daughters, Olyra, and Sola. Unlike engineered agonists, these products help naturally support GLP-1 signaling through dietary-based interventions. This week, HNGRY dives deeper into Daily30+ and 3 Farm Daughters to unpack the prebiotic fiber trend in the shadow of big pharma’s GLP-1 jabs.